.png){kind=icon}
返回
D
Daniela A. Bota
University of California
41H指数
314论文数
7.8K被引数
收录论文 85
发表时间
.png){kind=icon}
Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survivalBota, D.A.; Piccioni, D.E.; Duma, C.M.; Kesari, S.; Carrillo, J.A.; LaRocca, R.V.; Aiken, R.D.; Taylor, T.H.; Abedi, M.; Robles, R.M.; 等. 新诊断胶质母细胞瘤的个性化树突状细胞疫苗2期试验：3年随访及与生存期的相关性. Hum. Vaccines Immunother. 2025, 21, 2556591. [Google Scholar] [CrossRef].png)
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏
A pilot phase 1a clinical trial proposal to study the dose and safety of natural marine product Fucoidan to improve fatigue in the patients with newly diagnosed glioblastoma (GBM) on adjuvant Temozolomide (TMZ) therapy一项探索性Ia期临床试验方案，旨在研究天然海洋产物Fucoidan的剂量与安全性，以改善接受辅助替莫唑胺（TMZ）治疗的初诊胶质母细胞瘤（GBM）患者的疲劳症状。.png)
NEURO-ONCOLOGY
OAAI
NEURO-ONCOLOGYIF13.4
OAAI分享收藏A pilot phase 1b clinical trial proposal to study safety and improvement of fatigue by addition of natural marine product Fucoidan to the Temozolomide (TMZ) adjuvant chemotherapy for patients with newly diagnosed glioblastoma (GBM)一项探索性1b期临床试验方案，旨在研究通过在替莫唑胺（TMZ）辅助化疗中添加天然海洋产品岩藻聚糖硫酸酯（Fucoidan）来评估安全性及改善新诊断胶质母细胞瘤（GBM）患者疲劳的效果。NEURO-ONCOLOGYOAAI
NEURO-ONCOLOGYIF13.4
OAAI分享收藏